Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its three drug candidates – BL-M07D1, BL-M05D1, and izalontamab bretecan – have been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), spanning three antibody‑drug conjugate (ADC) programs in biliary tract cancer and gastric/gastroesophageal junction cancer.
Regulatory Milestone
| Asset | Modality / Target | BTD Indication | Population |
|---|---|---|---|
| BL-M07D1 (T-Bren) | Innovative self‑developed HER2‑targeting ADC with best‑in‑class potential | HER2‑expressing locally advanced or metastatic biliary tract cancer (BTC) | Patients who have failed platinum‑based chemotherapy |
| BL-M05D1 | Innovative Claudin18.2‑targeting ADC, built on the iza‑bren technology platform | CLDN18.2‑positive advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) | Patients who have previously received first‑line standard therapy |
| Izalontamab bretecan (iza‑bren, BL-B01D1) | First‑in‑class bispecific ADC – world’s first and only approved bispecific ADC | Recurrent or metastatic biliary tract cancer | Patients who have failed platinum‑based chemotherapy |
Agency: CDE of the NMPA (China) · Designation Date: 28 Sep 2026 · Next Steps: Continued clinical development under CDE expedited pathways, including priority interactions and accelerated review (timelines not disclosed).
Drug Profiles & Mechanisms
BL-M07D1 (T-Bren) – Anti‑HER2 ADC
- Molecule: Innovative, self‑developed HER2‑targeting ADC with best‑in‑class potential.
- Clinical Evidence: Has demonstrated significant antitumor efficacy in clinical trials (specific data not disclosed).
- Setting: Post‑platinum HER2‑expressing BTC – a biomarker‑selected population with very limited second‑line options.
BL-M05D1 – Claudin18.2 ADC
- Molecule: Innovative Claudin18.2‑targeting ADC.
- Platform Lineage: Built on the same technology platform and sharing the same “linker‑payload” platform as iza‑bren (izalontamab bretecan, BL-B01D1) – leveraging Biokin’s most clinically validated ADC chemistry.
- Target Rationale: Claudin18.2 is a tightly junction‑restricted antigen highly expressed in gastric and GEJ adenocarcinoma, making it a leading ADC and bispecific target in GI oncology.
Izalontamab Bretecan (iza‑bren) – Approved Bispecific ADC
- Molecule: A first‑in‑class, new‑concept bispecific ADC – the world’s first and only approved bispecific ADC.
- Approved Indications (NMPA): Recurrent or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma.
- New BTD: This designation covers recurrent or metastatic biliary tract cancer after failure of platinum‑based chemotherapy – extending the asset’s label trajectory into a new GI malignancy.
Market Impact & Outlook
- Platform‑Wide Validation: Three simultaneous BTDs across two target classes (HER2 and Claudin18.2) plus the company’s flagship bispecific ADC underscore the breadth of Biokin’s (SHA: 688506) ADC platform – the shared iza‑bren linker‑payload system now underpins multiple breakthrough‑designated assets.
- GI Oncology Push: Two of the three designations target biliary tract cancer, a rare but highly lethal GI malignancy where post‑platinum therapy remains a major unmet need; the third addresses second‑line CLDN18.2‑positive GC/GEJC, one of the most competitive segments in global oncology.
- Commercial Momentum for Iza‑Bren: Already NMPA‑approved in two indications, izalontamab bretecan adds a breakthrough pathway toward a potential third label in BTC, strengthening its position as the world’s only approved bispecific ADC.
- Regulatory Acceleration: BTD grants priority consultation, expedited review, and closer CDE interaction, potentially compressing development and filing timelines for all three assets in China.
- Execution Watch Items: Pivotal trial readouts for BL-M07D1 and BL-M05D1, registrational strategy for iza‑bren in BTC, and potential global expansion or partnerships (not disclosed).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory review, and commercialization of BL-M07D1, BL-M05D1, and izalontamab bretecan. Breakthrough Therapy Designation does not guarantee approval. Actual results may differ materially due to risks including clinical setbacks, safety findings, regulatory requirements, and competitive dynamics.-Fineline Info & Tech
